KJ 01
Alternative Names: KJ-01Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Kiji Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Graft-versus-host disease
Most Recent Events
- 18 Oct 2024 Preclinical trials in Graft-versus-host disease in France (Parenteral) prior to October 2024 (Kiji Therapeutics Pipeline, October 2024)
- 18 Oct 2024 Kiji Therapeutics plans the clinical trials for Graft-versus-host disease (GvHD) in the second half of 2025 (Kiji Therapeutics Pipeline, October 2024)